Irinotecan itself clears from your bloodstream relatively quickly, with a half-life of about 6 to 12 hours. But the story doesn’t end there. Your body converts irinotecan into an active metabolite called SN-38, which is 100 to 1,000 times more potent than the original drug and lingers considerably longer, with a half-life of 10 to 20 hours. Trace levels of SN-38 can still be detected in the blood days to weeks after a single infusion.
How the Drug Leaves Your Body
Irinotecan is a prodrug, meaning it doesn’t do much on its own. After your infusion, enzymes in your body convert it into SN-38, which is the compound that actually attacks cancer cells. SN-38 is fat-soluble, so your liver has to process it further before you can eliminate it. A specific enzyme (encoded by the UGT1A1 gene) attaches a sugar molecule to SN-38, making it water-soluble enough to leave through bile and urine.
Most of the drug exits through your digestive tract. Roughly 64% of the total dose ends up in feces, largely via bile. Another 11 to 20% of the parent drug is excreted through urine. Less than 1% of SN-38 itself leaves through the kidneys, which is why liver function matters so much for clearance.
The Timeline From Infusion to Clearance
Using the half-life as a guide, irinotecan itself drops to negligible blood levels within about two to three days. SN-38 takes longer. At 48 hours after a standard dose, measurable concentrations of SN-38 are still circulating in the blood. Research published in the British Journal of Cancer found that SN-38 plasma levels 2 days post-infusion were around 10 nanomolar, a concentration still high enough to inhibit cancer cell growth in lab models.
At 10 days, SN-38 concentrations drop to about 1 nanomolar. Even at 3 weeks post-infusion, researchers detected SN-38 at roughly 100 picomolar, an extremely low level but still present. So while the bulk of the drug clears within the first few days, very small amounts of SN-38 can persist in your system for weeks. This prolonged low-level exposure is one reason irinotecan remains effective against tumors between doses, but it also explains why side effects can develop days after treatment.
Why Clearance Time Varies Between People
Not everyone processes irinotecan at the same speed. The biggest factor is your UGT1A1 gene, which controls the enzyme responsible for deactivating SN-38. Some people carry a variant of this gene (called UGT1A1*28) that produces less of the enzyme. If you have this variant, SN-38 stays active in your body longer, increasing both its effectiveness and the risk of side effects like severe diarrhea and low white blood cell counts. Genetic testing for this variant is available and sometimes performed before starting treatment.
Liver function also plays a major role. Because the liver handles most of the drug’s breakdown and excretion through bile, any impairment slows clearance significantly. Patients with elevated bilirubin levels (a marker of liver function) typically receive reduced doses: those with bilirubin 1.5 to 3 times the normal limit may receive roughly half the standard dose, while those with bilirubin above 3 times normal receive less than a third of the full dose. These reductions exist specifically because an impaired liver can’t clear the drug fast enough, leading to dangerously prolonged exposure.
How Side Effects Track With Drug Clearance
The timing of irinotecan’s side effects reflects how long the drug and SN-38 remain active. There are two distinct patterns of diarrhea that illustrate this well.
Early-onset diarrhea happens within 24 hours of the infusion. This is caused by irinotecan itself stimulating the gut through a cholinergic mechanism, essentially a direct chemical effect that fades as irinotecan clears. It affects up to 10% of patients at higher doses.
Late-onset diarrhea is more common and more concerning. It typically begins around 6 days after treatment with the every-3-weeks schedule, or around 11 days with the weekly schedule. This delayed reaction is driven by SN-38 damaging the lining of the intestines as it’s excreted through bile into the gut. The fact that this side effect peaks nearly a week after infusion tells you something important: even though blood levels of SN-38 drop substantially within the first few days, the drug’s biological effects on your tissues continue well beyond that window.
What Dosing Schedules Tell You About Recovery
Irinotecan is given on one of three common schedules: weekly, every two weeks, or every three weeks. The every-3-weeks schedule uses a higher dose (around 350 mg/m²), while the weekly schedule uses a lower dose (around 125 mg/m²). These intervals are designed to give your body enough time to clear most of the drug and recover from its effects before the next round.
The three-week gap, for instance, aligns with the research showing trace SN-38 levels at that point. Your body has cleared the vast majority of the drug, your bone marrow has had time to replenish white blood cells, and your gut lining has begun to heal. The weekly schedule works differently: lower doses mean less SN-38 accumulation, so shorter recovery windows are sufficient, though the pattern of side effects shifts. Weekly dosing tends to cause more diarrhea, while the every-3-weeks schedule is more likely to cause drops in white blood cell counts.
In practical terms, the drug is functionally cleared from your body within a few days of each infusion, with residual trace amounts lingering for up to three weeks. The side effects and biological impact, however, can extend well beyond when the drug itself is detectable in your blood.